NEX Health Intelligence secures €1M to tackle hospital infection spread

Healthtech startup NEX Health Intelligence has raised €1 million in a pre-seed funding round led by Brighteye Ventures, with participation from Adeline Arts & Science, AFI Ventures, Momentous Ventures, the Conception X Angel Syndicate and a group of industry angel investors.

Healthcare-associated infections affect a significant proportion of hospital patients and contribute to longer hospital stays, operational disruption and rising healthcare costs. Highly resistant infections, in particular, continue to pose growing clinical and operational challenges for healthcare systems globally.

NEX Health Intelligence develops an AI-powered infection intelligence platform designed to help hospitals detect, predict and prevent healthcare-associated infections before they spread. The platform aims to enable hospitals to identify transmission risks earlier and implement more targeted infection prevention measures.

The company was founded by Dr Ashleigh Myall after his experience working on the NHS COVID-19 response highlighted how quickly infections can spread between vulnerable patients within hospitals. He later partnered with Dr Chang Ho Yoon to explore how AI could be applied to infection prevention and hospital safety.

While supporting the NHS COVID-19 response, I realised the real challenge wasn’t just the number of admissions - it was how quickly infections spread between vulnerable patients already inside hospitals,

said Dr Ashleigh Myall, who explained that the idea for NEX emerged during his PhD at Imperial, where he began developing AI systems to predict how infections could spread within hospitals.

Following its latest product release, the company reported a significant increase in infection control compliance rates. To date, NEX says its platform has supported infection safety across more than 40,000 patient admissions internationally.

NEX is currently working with NHS organisations in the United Kingdom, including evaluation projects across two London NHS Trusts and a deployment in the North West of England. Internationally, the company is operating at a military hospital in Southeast Asia and is expanding through projects in Malaysia.

The new funding will support the company’s expansion across UK and international hospitals, alongside regulatory and clinical safety work and the generation of clinical and economic evidence from live deployments.